This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut
by Zacks Equity Research
NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, citing lower COVID-19 vaccine uptake.
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US
by Zacks Equity Research
AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time this year.
Novavax to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA to remove the clinical hold on its two vaccine programs.
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
by Zacks Equity Research
DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings
by Kinjel Shah
AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera reports a narrower-than-expected loss in the third quarter. The company expects the current cash balance to provide a runway into mid-2027.
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
by Zacks Equity Research
Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales
by Zacks Equity Research
GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.
Regeneron to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter 2024 results.
Company News for Oct 28, 2024
by Zacks Equity Research
Companies In The Article Are: CPRI, TPR, CNC, SNY,AON
Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News
by Kinjel Shah
Roche announces third-quarter and nine-month results. Sanofi holds exclusive talks with CD&R to sell a 50% stake in Opella.
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
by Zacks Equity Research
SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.
Markets Mixed Again; DECK, SKX Beat After the Bell
by Mark Vickery
The Dow was -0.33% lower on the day, while all other major indexes were higher.
The Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi
by Zacks Equity Research
Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi are included in this Analyst Blog.
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale
by Zacks Equity Research
SNY is negotiating with CD&R to sell a 50% stake in its consumer healthcare business, Opella.
Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs
by Kinjel Shah
J&J tops third-quarter earnings and sales estimates. FDA approves new drugs of Pfizer, Roche and AbbVie.
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies
by Zacks Equity Research
Sanofi inks an agreement with Orano Med to develop next-generation radioligand medicines to treat rare cancers.
Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold
by Zacks Equity Research
NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the combo shot reported nerve damage.
Top Analyst Reports for Alibaba, Linde & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), Linde plc (LIN) and Abbott Laboratories (ABT), as well as a micro-cap stock Value Line, Inc. (VALU).
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
by Zacks Equity Research
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals
by Zacks Equity Research
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
Roche Wins FDA Nod for Breast Cancer Drug in First-Line Setting
by Zacks Equity Research
RHHBY obtains FDA approval for Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Should Value Investors Buy Sanofi (SNY) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
by Zacks Equity Research
KYMR will initiate dosing in a phase I study on KT-621, an investigational first-in-class once daily, oral STAT6 degrader, following IND clearance by the FDA.
Regeneron Gains 13.5% Year to date: How to Play the Stock?
by Zacks Equity Research
REGN maintains momentum as Eylea HD gains traction and Dupixent maintains momentum, even as lead drug Eylea faces challenges.